Tags

Main Content

Top Content

Directory of Key words from the Journal and the latest article from it.

Autologous muscle-derived cellsView Articles

Volume 12, Number 3Meeting Reviews

Best of the AUA Annual Meeting

Meeting Review

Dean G AssimosEllen ShapiroMichael B ChancellorJ Curtis NickelClaus G RoehrbornMichael K BrawerAkira Furuta

Highlights From the 2010 American Urological Association Meeting, May 29-June 3, 2010, San Francisco, CA [Rev Urol. 2010;12(2/3):e134-e146 doi: 10.3909/riu0500]

Autologous muscle-derived cellsNocturiaBotulinum toxinProstate-specific antigenUrosepsisShock wave lithotripsyTransrectal ultrasound prostateEscherichia coliSynthetic mesh slingProstatic urethral liftPRX3.02

Average sale priceView Articles
Average sales priceView Articles
Average wholesale priceView Articles
Average-risk menView Articles

Volume 19, Number 2Review Articles

The American Urological Association’s Prostate Cancer Screening Guideline: Which Cancers Will Be Missed in Average-risk Men Aged 40 to 54 Years?

Cancer Screening Update

Thomas E MoodyCurtis L SpraitzarElizabeth EisenhartScott Tully Jr

To determine the impact of the American Urological Association’s (AUA) guideline for early detection of prostate cancer that recommends against routine screening in men aged 40 to 54 years at average risk (eg, white men without a family history of prostate cancer), we undertook a study of 973 men who previously underwent a prostate biopsy at Urology Centers of Alabama (UCA) over the 5-year period from 2010 to 2014. We retrospectively reviewed the results of the prostate biopsies performed by urologists at UCA—and, where applicable, the final surgical pathology results and compared the results by race and family history. In white men with a family history of prostate cancer, 47% had cancer and 30% had Gleason score (GS) ≥ 7 disease. In white men without a family history of prostate cancer, 32% had cancer and 23% had GS ≥ 7 disease. By comparison, in African American men with a family history of prostate cancer, 56% had cancer and 42% had GS ≥ 7 disease. In African American men without a family history, 42% had cancer and 29% had GS ≥ 7 disease. In our study, 144 of 456 (32%) of the group of average-risk men had cancer and 105 of 456 (23%) had GS ≥ 7 cancer. Had the AUA guidelines been followed, these cancers would have been missed or the diagnoses delayed. [Rev Urol. 2017;19(2):106–112 doi: 10.3909/riu0748] © 2017 MedReviews®, LLC

Prostate cancerProstate-specific antigenAUA screening guidelineAverage-risk men

AzoospermiaView Articles

Volume 17, Number 1Case Review

Rare Case of Monozygotic Twins Diagnosed With Klinefelter Syndrome During Evaluation for Infertility

Edmund S SabaneghYagil Barazani

Although neither Klinefelter syndrome nor monozygotic twins are particularly rare (1/667 male births and 3-4/1000 live births, respectively), the occurrence of both in the same pregnancy (ie, identical twins with Klinefelter syndrome) is exceedingly rare and has only been reported three times previously in the literature. This report describes the fourth ever reported case of monozygotic twins with Klinefelter syndrome (who presented to our male fertility clinic with failure to conceive) and sheds interesting light on the reproductive concordance observed with this rare clinical entity. To our knowledge, this is the first reported case of monozygotic twins with Klinefelter syndrome that describes the infertility workup and outcomes of microsurgical testicular sperm extraction. [Rev Urol. 2015;17(1):42-45 doi: 10.3909/riu0628] © 2015 MedReviews®, LLC

Klinefelter syndromeMicrosurgical testicular sperm extractionAzoospermiaSertoli only syndromeGerm cell aplasia

Bacille Calmette-GuerinView Articles

Volume 5, Number 2Meeting Reviews

Advances in the Medical Treatment of Prostate Cancer, Bladder Cancer, Renal Cell Cancer, and Benign Prostatic Hyperplasia

Highlights from the XVIIth Congress of the European Association of Urology, Birmingham, UK

Claus G RoehrbornBob DjavanMesut RemziChristian Seitz

Prostate cancerBenign prostatic hyperplasiaBladder cancerLower urinary tract symptomsProstate-specific antigenRadical prostatectomyRadical nephrectomyNomogramsTamsulosinAlfuzosinFinasterideDutasterideBicalutamideBacille Calmette-GuerinPermixonRenal cell cancerTransrectal ultrasound-guided biopsyVirtual cystoscopy

Bacille Calmette-Guérin therapyView Articles

Volume 5, Number 3Meeting Reviews

Best of the 2003 AUA Annual Meeting

Highlights from the 2003 Annual Meeting of the American Urological Association, April 26-May 1, 2003

Dean G AssimosEllen ShapiroAlan W PartinMichael B ChancellorJ Curtis NickelJacob RajferClaus G RoehrbornMichael K BrawerRandall B MeachamBob DjavanArie S BelldegrunAllan J PantuckMesut RemziMichael DobrovitsMatthew B GretzerKazumasa Torimoto

Prostate cancerRenal cell carcinomaBenign prostatic hyperplasiaDepressionBladder cancerLower urinary tract symptomsUrinary tract infectionProstate-specific antigenNephrolithiasisOveractive bladderRadical prostatectomyPeyronie’s diseaseGleason scoreTransrectal ultrasoundErectile dysfunctionChronic prostatitis/chronic pelvic pain syndromeAcute urinary retentionInternational Prostate Symptom ScoreBacille Calmette-Guérin therapyChronic Prostatitis Symptom IndexMTOPS trialPLESS studyProstate tumor markersSELDI-TOF

Bacille Calmette-Guérin vaccineView Articles
Bacillus Calmette-GuérinView Articles

Volume 10, Number 4Review Articles

Bacillus Calmette-Guérin Failures and Beyond: Contemporary Management of Non–Muscle-Invasive Bladder Cancer

Management Review

Michael S CooksonRichard E GreenbergH Barton GrossmanThomas E KeaneMichael A O'Donnell

In the United States, bacillus Calmette-Guérin (BCG) is the treatment most used for superficial bladder cancer. Patients with carcinoma in situ (CIS) treated with intravesical BCG plus interferon have a 60% to 70% chance of a complete and durable response if they were never treated with BCG or if they failed only 1 prior induction or relapsed more than a year from induction. Intravesical gemcitabine is safe, but its usefulness for BCG-refractory patients is unclear. Valrubicin, approved for intravesical treatment of BCGrefractory CIS of the bladder, has efficacy and acceptable toxicity. Cystectomy should be considered in high-risk, non–muscle-invasive cancer, particularly if intravesical therapy failed. [Rev Urol. 2008;10(4):281-289]

Bacillus Calmette-GuérinBladder cancerCystectomyGemcitabine

BacteriaView Articles
BarriersView Articles

Volume 18, Number 4Review Articles

Barriers to Accessing Urethroplasty

Treatment Update

David O SussmanGordon A BrownMichael J ConsoloKirin K SyedChristopher RobisonJacob McFaddenDavid I ShalowitzBradley D Figler

Urethroplasty is an effective treatment for men with anterior urethral strictures, but is utilized less frequently than ineffective treatments such as internal urethrotomy. We sought to identify provider-level barriers to urethroplasty. An anonymous online survey was emailed to all Mid-Atlantic American Urological Association members. Six scenarios in which urethroplasty was the most appropriate treatment were presented. Primary outcome was recommendation for urethroplasty in ≥ three clinical scenarios. Other factors measured include practice zip code, urethroplasty training, and proximity to a urethroplasty surgeon. Multivariate logistic regression identified factors associated with increased likelihood of urethroplasty recommendation. Of 670 members emailed, 109 (16%) completed the survey. Final analysis included 88 respondents. Mean years in practice was 17.2. Most respondents received formal training in urethroplasty: 43 (49%) in residency, 5 (6%) in fellowship, and 10 (11%) in both; 48 respondents (55%) had a urethroplasty surgeon in their practice, whereas 18 (20%) had a urethroplasty surgeon within 45 minutes of his or her primary practice location. The only covariate that was associated with an increased likelihood of recommending urethroplasty in ≥ three scenarios was formal urethroplasty training. Most members (68%) reported no barriers to referring patients for urethroplasty; the most common barriers cited were long distance to urethroplasty surgeon (n = 13, 15%) and concern about complications (n = 8, 9%). Urethroplasty continues to be underutilized in men with anterior urethral strictures, potentially due to lack of knowledge dissemination and access to a urethroplasty surgeon. Appropriate urethroplasty utilization may increase with greater exposure to urethroplasty in training. [Rev Urol. 2016;18(4):188-193 doi: 10.3909/riu0731] © 2016 MedReviews®, LLC

UrethroplastyUrethral stricturesBarriersPhysician practice patterns

Basic scienceView Articles

Volume 6, Number 3Meeting Reviews

Best of the 2004 AUA Annual Meeting

Highlights from the 2004 Annual Meeting of the American Urological Association, May 8-13, 2004

Dean G AssimosEllen ShapiroAlan W PartinMichael B ChancellorJ Curtis NickelJacob RajferClaus G RoehrbornMichael K BrawerRandall B MeachamKevin M SlawinBob DjavanArie S BelldegrunMichael P O'LearyJohn S LamStephen J FreedlandYan Kit FongTheodore AnagnostouOleg ShvartsNaveen Kella

Prostate cancerRenal cell carcinomaObesityRobotic surgeryKidney stonesLaparoscopyBenign prostatic hyperplasiaBladder cancerOncologyLower urinary tract symptomsProstate-specific antigenOveractive bladderRadical prostatectomyMale infertilityUrolithiasisErectile dysfunctionPediatric urologyChronic prostatitisIncontinenceTumor markersBasic science

BCG shortageView Articles

Volume 21, Number 4Review Articles

Intravesical Therapy for Non-muscle Invasive Bladder Cancer—Current and Future Options in the Age of Bacillus Calmette-Guerin Shortage

Treatment Update

Izak FaienaKarim ChamieVishnukamal GollaAndrew T Lenis

Non-muscle invasive bladder cancer (NMIBC) is a common and burdensome malignancy. A substantial proportion of patients with intermediate- and high-risk disease will progress to invasive bladder cancer and are at a significant risk for metastasis and death. Bacillus Calmette-Guerin (BCG) therapy for selected cases has been the standard of care for nearly 40 years. Unfortunately, a world-wide shortage has made BCG challenging to obtain. Furthermore, recurrences and progressions do occur. With the US Food and Drug Administration creating a clear path to drug approval for novel treatments, many therapies have been tested, including intravesical cytotoxic chemotherapy, intravesical immunotherapy, systemic immunotherapy, and novel agents, such as gene therapy and targeted therapy. In this review, we highlight ongoing clinical trials. [Rev Urol. 2019;21(4):145–153] © 2020 MedReviews®, LLC

ImmunotherapyNon-muscle invasive bladder cancerBladder cancerIntravesical treatmentBCG shortage

BCG therapyView Articles
Behavioral therapyView Articles
BenignView Articles
Benign MassView Articles
Benign prostaticView Articles
Benign prostatic enlargementView Articles
Benign prostatic hyperplasiaView Articles
Benign prostatic hyperplasia (BPH)View Articles
Benign prostatic hypertrophyView Articles

Volume 17, Number 3Review Articles

The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy

Management Update

Ojas ShahHerbert LeporGanesh SivarajanMichael S BorofskyJames E Lingeman

Lower urinary tract symptoms (LUTS) secondary to benign prostatic hypertrophy (BPH) are among the most common medical issues for aging men. Population-based studies suggest that 13.8% of men in their 40s and more than 40% of men over age 60 have BPH. When LUTS are refractory to medical therapy and bothersome enough to warrant surgical intervention, transurethral resection of the prostate and open simple prostatectomy have been the historical reference-standard procedures for decades. Both procedures are highly effective and offer durable improvements in urinary functional outcomes. However, they also have the potential for considerable perioperative complications and morbidity. In an effort to limit surgical morbidity, a variety of minimally invasive surgical techniques to treat BPH have been introduced. Herein we present a comprehensive, evidence-based review of the efficacy and safety profile of modern minimally invasive treatments for large-gland BPH. [Rev Urol. 2015;17(3):140-149 doi: 10.3909/riu0675] © 2015 MedReviews®, LLC

Lower urinary tract symptomsRobotic simple prostatectomyBenign prostatic hypertrophyGreenLight photovaporizationHolmium laser enucleation of the prostate (HoLEP)

Benign prostatic obstructionView Articles
Benign prostatic specific antigenView Articles

Volume 11, Number 2Meeting Reviews

Best of the 2009 AUA Annual Meeting

Highlights From the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL

Dean G AssimosEllen ShapiroAlan W PartinMichael B ChancellorStacy LoebJ Curtis NickelClaus G RoehrbornMichael K BrawerNaoki YoshimuraArie S BelldegrunB ShuchF Pouliot

Prostate cancer screeningObesityBenign prostatic hyperplasiaLower urinary tract symptomsVesicoureteral refluxNephrolithiasisStress urinary incontinenceInflammationSilodosinHormonal therapyTumor markersTMPRSS2ERG4-Kallikrein panelBotulinum toxin type AMale voiding dysfunctionBenign prostatic specific antigenRoux-en-Y gastric bypass surgeryGenitourinary pain indexUPOINT clinical phenotype systemNephron-sparing surgeryWatchful waitingLaparoscopy for adrenal cortical carcinomaPartial adrenalectomyUrethral traumaPediatric urethral strictureEnteric urologic surgery

Benign prostatichyperplasiaView Articles
Benignprostatic hyperplasia (BPH)View Articles
BethanecholView Articles
BicalutamideView Articles

Volume 5, Number 2Meeting Reviews

Advances in the Medical Treatment of Prostate Cancer, Bladder Cancer, Renal Cell Cancer, and Benign Prostatic Hyperplasia

Highlights from the XVIIth Congress of the European Association of Urology, Birmingham, UK

Claus G RoehrbornBob DjavanMesut RemziChristian Seitz

Prostate cancerBenign prostatic hyperplasiaBladder cancerLower urinary tract symptomsProstate-specific antigenRadical prostatectomyRadical nephrectomyNomogramsTamsulosinAlfuzosinFinasterideDutasterideBicalutamideBacille Calmette-GuerinPermixonRenal cell cancerTransrectal ultrasound-guided biopsyVirtual cystoscopy

Bifid uretersView Articles

Volume 15, Number 3Case Review

Obstructed Bifid Uretereric System Causing Unilateral Hydronephrosis

Amyn BhamaniManoj Srivastava

Bifid ureters are a common malformation of the urinary system. In clinical practice, hydronephrosis resulting from obstruction of such a system is rare. The authors present a case involving an 88-year-old man admitted to the hospital with symptoms of renal failure, where bifid ureters were found incidentally in a hydronephrotic kidney during an emergency nephrostomy. This had been missed on a previous CT scan, resulting in a unique therapeutic dilemma. [ Rev Urol. 2013;15(3):131-134 doi: 10.3909/riu0578] © 2013 MedReviews®, LLC

Bifid uretersHydronephrosisNephrostomy